/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6...
Related Keywords
Puerto Rico , Japan , United States , Canada , Turkey , Japanese , American , Jessica Akopyan , Roberta Bradway , Provention Bio , Amgen , European Society For Medical Oncology Congress , American Society Of Clinical Oncology , Research Development , Takeda Pharmaceutical Company , Astrazeneca , Therapeutics Inc , European Society Of Cardiology , Arrakis Therapeutics Inc , European Union , Teneobio Inc , Research Development Acquired , Kyowa Kirin Co Ltd , Regeneron Pharmaceuticals Inc , Plexium Inc , Beigene Ltd , Alexion Pharmaceuticals Inc , Brazilian National Health Surveillance Agency , Exchange Commission , Biomedicines Inc , Committee For Medicinal Products Human , Amgen Inc , Health Canada , Chemocentryx Inc , Acquired In Process Research , Five Prime Therapeutics , Average Selling Price , Sales Detail , Operating Margin , Tax Rate , Operating Expenses , Five Prime , Diluted Shares , Quarter Product , Medicinal Products , Human Use , American Society , Clinical Oncology , International Association , Lung Cancer World Conference , Lung Cancer , Revolution Medicines , European Society , Medical Oncology Congress , Janssen Pharmaceutica , Regeneron Pharmaceuticals , Alexion Pharmaceuticals , Accepted Accounting Principles , Free Cash Flow , Dow Jones Industrial Average , Best Workplaces , Great Place , Generate Biomedicines , Arrakis Therapeutics , Balance Sheets , Year Ending December , Rate Guidance ,
comparemela.com © 2020. All Rights Reserved.